Combining Photochemical Oxyfunctionalization and Enzymatic Catalysis for the Synthesis of Chiral Pyrrolidines and Azepanes
- PMID: 39772597
- PMCID: PMC11744798
- DOI: 10.1021/acs.joc.4c02228
Combining Photochemical Oxyfunctionalization and Enzymatic Catalysis for the Synthesis of Chiral Pyrrolidines and Azepanes
Abstract
Chiral heterocyclic alcohols and amines are frequently used building blocks in the synthesis of fine chemicals and pharmaceuticals. Herein, we report a one-pot photoenzymatic synthesis route for N-Boc-3-amino/hydroxy-pyrrolidine and N-Boc-4-amino/hydroxy-azepane with up to 90% conversions and >99% enantiomeric excess. The transformation combines a photochemical oxyfunctionalization favored for distal C-H positions with a stereoselective enzymatic transamination or carbonyl reduction step. Our study demonstrates a mild and operationally simple asymmetric synthesis workflow from easily available starting materials.
Conflict of interest statement
The authors declare no competing financial interest.
Figures


Similar articles
-
Microbial/enzymatic synthesis of chiral drug intermediates.Adv Appl Microbiol. 2000;47:33-78. doi: 10.1016/s0065-2164(00)47001-2. Adv Appl Microbiol. 2000. PMID: 12876794 Review.
-
Vitamin B6-Based Biomimetic Asymmetric Catalysis.Acc Chem Res. 2023 May 2;56(9):1097-1117. doi: 10.1021/acs.accounts.3c00053. Epub 2023 Apr 18. Acc Chem Res. 2023. PMID: 37071776
-
Stereoselective Three-Step One-Pot Cascade Combining Amino- and Biocatalysis to Access Chiral γ-Nitro Alcohols.Angew Chem Int Ed Engl. 2022 Oct 4;61(40):e202209159. doi: 10.1002/anie.202209159. Epub 2022 Sep 5. Angew Chem Int Ed Engl. 2022. PMID: 35983936 Free PMC article.
-
Photoredox/Enzymatic Catalysis Enabling Redox-Neutral Decarboxylative Asymmetric C-C Coupling for Asymmetric Synthesis of Chiral 1,2-Amino Alcohols.JACS Au. 2023 Oct 31;3(11):3005-3013. doi: 10.1021/jacsau.3c00366. eCollection 2023 Nov 27. JACS Au. 2023. PMID: 38034963 Free PMC article.
-
Green and Enantioselective Synthesis via Cascade Biotransformations: From Simple Racemic Substrates to High-Value Chiral Chemicals.Chem Asian J. 2024 Oct 1;19(19):e202400565. doi: 10.1002/asia.202400565. Epub 2024 Aug 21. Chem Asian J. 2024. PMID: 38954385 Review.
References
-
- Vitaku E.; Smith D. T.; Njardarson J. T. Analysis of the Structural Diversity, Substitution Patterns, and Frequency of Nitrogen Heterocycles among U.S. FDA Approved Pharmaceuticals: Miniperspective. J. Med. Chem. 2014, 57 (24), 10257–10274. 10.1021/jm501100b. - DOI - PubMed
- Kittakoop P.; Mahidol C.; Ruchirawat S. Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation. Curr. Top. Med. Chem. 2013, 14 (2), 239–252. 10.2174/1568026613666131216105049. - DOI - PubMed
- Roughley S. D.; Jordan A. M. The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates. J. Med. Chem. 2011, 54 (10), 3451–3479. 10.1021/jm200187y. - DOI - PubMed
-
- Zhang J.; Wei Y.; Zhou X.; Yang K.; Sun Y.. PARP1 inhibitor and application thereof. CN 117447449A, 2022.
- Freeman D. B.; Hopkins T. D.; Mikochik P. J.; Vacca J. P.; Gao H.; Naylor-Olsen A.; Rudra S.; Li H.; Pop M. S.; Villagomez R. A.; Lee C.; Li H.; Zhou M.; Saffran D. C.; Rioux N.; Hood T. R.; Day M. A. L.; McKeown M. R.; Lin C. Y.; Bischofberger N.; Trotter B. W. Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9 for MYC-Dependent Cancers. J. Med. Chem. 2023, 66 (23), 15629–15647. 10.1021/acs.jmedchem.3c01233. - DOI - PMC - PubMed
- Petri G. L.; Raimondi M. V.; Spanò V.; Holl R.; Barraja P.; Montalbano A. Pyrrolidine in Drug Discovery: A Versatile Scaffold for Novel Biologically Active Compounds. Top. Curr. Chem. 2021, 379 (5), 3410.1007/s41061-021-00347-5. - DOI - PMC - PubMed
- Mikochik P.; Vacca J.; Freeman D.; Tasker A.. Compounds, Compositions, and Methods for Modulating Cdk9 Activity. CA 3118472 A1, 2020.
- McGrath N. A.; Brichacek M.; Njardarson J. T. A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives. J. Chem. Educ. 2010, 87 (12), 1348–1349. 10.1021/ed1003806. - DOI
-
- Hughes D. L. Patent Review of Manufacturing Routes to Fifth-Generation Cephalosporin Drugs. Part 2, Ceftaroline Fosamil and Ceftobiprole Medocaril. Org. Process Res. Dev. 2017, 21 (6), 800–815. 10.1021/acs.oprd.7b00143. - DOI
-
- Hoegenauer K.; Soldermann N.; Zécri F.; Strang R. S.; Graveleau N.; Wolf R. M.; Cooke N. G.; Smith A. B.; Hollingworth G. J.; Blanz J.; Gutmann S.; Rummel G.; Littlewood-Evans A.; Burkhart C. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Med. Chem. Lett. 2017, 8 (9), 975–980. 10.1021/acsmedchemlett.7b00293. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources